Department of Brain Health News
The UNLV department of brain health advances research, education, and practice to improve the care and treatment of individuals with brain disorders. Our students receive guidance from faculty who specialize in a range of areas from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.
Current Brain Health News
Alzheimer’s treatment studies offer hope as UNLV expert predicts new potential drugs, biomarkers will yield critical insight for future development.
Professor Chih-Huang "Jeffrey" Yu says the new and unique method can make rehab a more effective experience for patients.
Amanda Osse is the first recipient of the award named in honor of Nathan Lindsay, who passed away after a 15-year battle with Alzheimer's disease.
A collection of news stories highlighting expert insights, research, and academic achievement.
The director of UNLV’s Occupational Therapy program likens her field to the nest-building skills of birds.
UNLV faculty and students screen community members in Las Vegas, Henderson, and Pahrump.
Brain Health In The News
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.
The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.
Considering current developments in Alzheimer’s drugs, a US expert has predicted that the industry should “be prepared for more complex biological therapies that require intravenous infusion and vigilant monitoring for side effects; more like cancer therapies,” according to Dr Jeffrey Cummings, Alzheimer’s clinician-scientist and research professor at the School of Integrated Health Sciences, University of Nevada, Las Vegas.
The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. On the heels of newly FDA-approved drugs Aduhelm (aducanumab) in 2021 and Leqembi (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.
Recovering from a life-altering stroke can be a long and arduous journey when an irascible demeanor and a litany of frustrations prolong a patient's return to normalcy. Stroke is the leading cause of death in the United States and a major cause of serious disability for adults, according to the Centers for Disease Control and Prevention.
